Imunon to present Phase 3 OVATION trial of IMNN-001

IMUNON (IMNN) announced that a trials-in-progress abstract on the ongoing Phase 3 OVATION 3 clinical trial of IMNN-001, its investigational therapy for the treatment of women with newly diagnosed advanced ovarian cancer, was accepted for poster presentation at the European Society for Medical Oncology, ESMO, Congress 2025, being held October 17-21, 2025 in Berlin, Germany. IMNN-001, based on IMUNON’s proprietary TheraPlas technology platform, is an interleukin-12, IL-12, DNA plasmid vector incorporated in a nanoparticle delivery system, enabling cell transfection followed by persistent, local production and secretion of the IL-12 protein in the tumor microenvironment. IMNN-001 is the first therapy to achieve a clinically effective response in advanced ovarian cancer including benefits in both progression-free survival and overall survival in a first-line treatment setting when used with standard of care chemotherapy.